3-HIB
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562571

CAS#: 1219589-99-7

Description: 3-HIB is a paracrine regulator of trans-endothelial fatty acid transport.


Chemical Structure

img
3-HIB
CAS# 1219589-99-7

Theoretical Analysis

MedKoo Cat#: 562571
Name: 3-HIB
CAS#: 1219589-99-7
Chemical Formula: C4H7NaO3
Exact Mass: 0.00
Molecular Weight: 126.080
Elemental Analysis: C, 38.10; H, 5.60; Na, 18.23; O, 38.07

Price and Availability

Size Price Availability Quantity
250mg USD 300 2 Weeks
1g USD 680 2 Weeks
Bulk inquiry

Synonym: 3-HIB; 3 HIB; 3HIB;

IUPAC/Chemical Name: Sodium 3-Hydroxyisobutyrate

InChi Key: RBJZIQZDAZLXEK-UHFFFAOYSA-M

InChi Code: InChI=1S/C4H8O3.Na/c1-3(2-5)4(6)7;/h3,5H,2H2,1H3,(H,6,7);/q;+1/p-1

SMILES Code: CC(CO)C([O-])=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 126.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mardinoglu A, Gogg S, Lotta LA, Stančáková A, Nerstedt A, Boren J, Blüher M, Ferrannini E, Langenberg C, Wareham NJ, Laakso M, Smith U. Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes. EBioMedicine. 2018 Jan;27:151-155. doi: 10.1016/j.ebiom.2017.12.008. Epub 2017 Dec 7. PubMed PMID: 29246479; PubMed Central PMCID: PMC5828558.

2: Haufe S, Engeli S, Kaminski J, Witt H, Rein D, Kamlage B, Utz W, Fuhrmann JC, Haas V, Mähler A, Schulz-Menger J, Luft FC, Boschmann M, Jordan J. Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals. Nutr Metab Cardiovasc Dis. 2017 Oct;27(10):858-864. doi: 10.1016/j.numecd.2017.07.001. Epub 2017 Jul 11. PubMed PMID: 28958691.

3: Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20. PubMed PMID: 28536030.

4: Harris LLS, Smith GI, Patterson BW, Ramaswamy RS, Okunade AL, Kelly SC, Porter LC, Klein S, Yoshino J, Mittendorfer B. Alterations in 3-Hydroxyisobutyrate and FGF21 Metabolism Are Associated With Protein Ingestion-Induced Insulin Resistance. Diabetes. 2017 Jul;66(7):1871-1878. doi: 10.2337/db16-1475. Epub 2017 May 4. PubMed PMID: 28473464; PubMed Central PMCID: PMC5482083.

5: Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, Rhee J, Hoshino A, Kim B, Ibrahim A, Baca LG, Kim E, Ghosh CC, Parikh SM, Jiang A, Chu Q, Forman DE, Lecker SH, Krishnaiah S, Rabinowitz JD, Weljie AM, Baur JA, Kasper DL, Arany Z. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016 Apr;22(4):421-6. doi: 10.1038/nm.4057. Epub 2016 Mar 7. PubMed PMID: 26950361; PubMed Central PMCID: PMC4949205.

6: Centers for Disease Control and Prevention (CDC). Changes in measurement of Haemophilus influenzae serotype b (Hib) vaccination coverage --- National Immunization Survey, United States, 2009. MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1069-72. PubMed PMID: 20798669.

7: Zhao Z, Smith PJ, Luman ET. Trends in early childhood vaccination coverage: progress towards US Healthy People 2010 goals. Vaccine. 2009 Aug 6;27(36):5008-12. doi: 10.1016/j.vaccine.2009.05.074. Epub 2009 Jun 12. PubMed PMID: 19524616.

8: Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007 Jun;26(6):496-500. PubMed PMID: 17529866.

9: Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, Ramsay ME, Deeks JJ, Moxon ER. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000 Nov 8;284(18):2334-40. PubMed PMID: 11066183.

10: Cellesi C, Rossolini A, Balestrieri G, Marinacci G, Pavesio D, Soŕanzo ML, Titone L, Vierucci A, Stroffolini T. Retrospective survey on the epidemiology of H. influenzae type B meningitis in Italy (1987-91). New Microbiol. 1995 Apr;18(2):183-6. PubMed PMID: 7603345.

11: Vadheim CM, Greenberg DP, Eriksen E, Hemenway L, Bendana N, Mascola L, Ward JI. Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group. Arch Pediatr Adolesc Med. 1994 Jan;148(1):51-6. PubMed PMID: 8143010.

12: Crisma M, Valle G, Bonora GM, Toniolo C, Cavicchioni G. The beta-bend ribbon spiral. Synthesis and conformational analysis in solution and in the crystal state of depsipeptides containing alpha-hydroxyisobutyric acid. Int J Pept Protein Res. 1993 Jun;41(6):553-60. PubMed PMID: 8349413.

13: Samore MH, Siber GR. Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b. J Infect Dis. 1992 May;165(5):945-8. PubMed PMID: 1533239.

14: Claesson BA, Trollfors B, Lagergard T, Taranger J, Bryla D, Otterman G, Cramton T, Yang Y, Reimer CB, Robbins JB, et al. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr. 1988 May;112(5):695-702. PubMed PMID: 3361379.